| Aug 30 |
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
|
| Aug 30 |
Full study data back Alnylam heart drug’s benefit, but leave doctors with tough choices
|
| Aug 29 |
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability
|
| Aug 28 |
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
|
| Aug 23 |
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
|
| Aug 21 |
High Growth Tech Stocks To Watch In August 2024
|
| Aug 21 |
3 US Stocks Estimated To Be Trading Below Their Intrinsic Value In August 2024
|
| Aug 21 |
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q2
|
| Aug 20 |
Investing in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago would have delivered you a 234% gain
|
| Aug 14 |
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 47% Undervaluation?
|
